"
Gregg Gilbert Joins Mirador Therapeutics as Chief Financial Officer - Revolutionizing Precision Medicines
"
Mirador Therapeutics, Inc., a cutting-edge precision medicine company dedicated to developing groundbreaking therapeutics for immunology and inflammation, has appointed Gregg Gilbert as its new chief financial officer. With more than 25 years of expertise in biopharma equity research analysis and investment banking, Mr. Gilbert brings a wealth of knowledge to his new role.
"
A Strategic Addition to the Team
"
Mark C. McKenna, Chairman and CEO of Mirador, expressed his excitement about the appointment, stating, "Since its inception earlier this year with a substantial capital infusion of over $400 million, Mirador has been actively expanding its portfolio of innovative precision therapies for immunology and inflammation. Gregg's extensive Wall Street background, spanning corporate and investor relations, will be instrumental in steering our growth strategy moving forward."
"
Extensive Industry Experience
"
Prior to joining Mirador, Mr. Gilbert held the position of managing director at Bank of America Securities, where he specialized in healthcare investment banking and provided strategic guidance to life sciences companies at various developmental stages. His illustrious career includes serving as a leading equity research analyst and advisor to top-tier institutional investors in the biopharma sector. With over 15 years at Bank of America Merrill Lynch and experience at reputable firms like Deutsche Bank and Truist Securities, Mr. Gilbert's arrival signifies a significant addition to Mirador's leadership team.
"
Driving Innovation in Precision Medicine
"
Commenting on his new role, Mr. Gilbert stated, "Mirador is poised to deliver exceptional value to its stakeholders and address the needs of millions suffering from immune-mediated and inflammatory diseases. I am honored to join this highly skilled and collaborative team as CFO and eager to contribute to our mission of advancing groundbreaking precision medicines in the field of immunology and inflammation."
"
About Mirador Therapeutics
"
Mirador is a forward-thinking precision medicine company dedicated to developing cutting-edge precision medicines for immunology and inflammation. Leveraging its proprietary Mirador360 TM development engine, the company aims to revolutionize precision medicine by rapidly advancing new therapies for patients with chronic immune-mediated inflammatory and fibrotic diseases. Established in 2024, Mirador has secured over $400 million from prominent life sciences investors and is headquartered in San Diego, CA. For more details, visit www.miradortx.com and connect with us on LinkedIn.
CONTACT: Media
Dan Budwick, 1AB
Steve Klass, 1AB